- Home
- / Valeo Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Valeo Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.5
2022-05-27
Market Capitalization
$52 M
2022-05-27
Revenue
$53.9 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CAD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 4.4M | 6.6M | 7.5M | 13.6M | 27.7M | 53.9M |
| Cost of goods sold | 3.5M | 5.2M | 6.1M | 8.8M | 19.1M | 37.6M |
| Gross profit | 979.0K | 1.7M | 1.4M | 4.8M | 8.7M | 16.4M |
| Gross profit margin, % | 22.3% | 25.1% | 18.5% | 35.4% | 31.3% | 30.3% |
| Operating expense total | 3.2M | 5.1M | 5.5M | 16.3M | 25.0M | 31.1M |
| Depreciation and amortization | 44.0K | 78.0K | 259.0K | 990.0K | 2.6M | 2.6M |
| EBITDA | (2.2M) | (3.4M) | (4.1M) | (11.5M) | (16.4M) | (14.8M) |
| EBITDA margin, % | -51.1% | -51.8% | -54.7% | -84.6% | -59.0% | -27.4% |
| EBIT | (2.3M) | (3.5M) | (4.1M) | (12.3M) | (18.8M) | (17.2M) |
| EBIT margin, % | -52.1% | -53.0% | -55.5% | -91.0% | -67.8% | -32.0% |
| Interest income | 1.0K | 1.0K | 1.0K | 173.0K | 3.7M | |
| Interest expense | 265.0K | 134.0K | 614.0K | 1.4M | 6.5M | 13.8M |
| Pre tax profit | (2.4M) | (3.6M) | (4.8M) | (14.2M) | (26.9M) | (27.8M) |
| Income tax expense | 36.0K | (1.2M) | ||||
| Net Income | (2.4M) | (3.6M) | (4.8M) | (14.2M) | (25.7M) | (27.8M) |